Endo Pharmaceuticals Submits Citizen Petition To FDA Regarding Lidoderm(R)

CHADDS FORD, PA -- (MARKET WIRE) -- December 19, 2006 -- Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) announced today the submission of a Citizen Petition with the U.S. Food and Drug Administration requesting that the FDA apply existing bioequivalence regulations to any Abbreviated New Drug Application (ANDA) seeking regulatory approval of a generic drug product that references Endo's Lidoderm® (lidocaine topical patch 5%).